Table 2 Univariate and multivariate Cox regression analyses for the full cohort (N = 288).

Age

≥ median vs. < median

0.83; 0.62–1.1

0.21

0.9;

0.7–1.2

0.40

Gender

Male vs. Female

0.79; 0.52–1.2

0.30

0.99;

0.7–1.4

0.97

Cirrhosis

Yes vs. No

1.1;

0.7–1.7

0.66

0.89;

0.61–1.3

0.53

Tumor Size

≥ median vs. < median

1.2;

0.91–1.7

0.18

1.1;

0.84–1.4

0.54

Extrahepatic

Yes vs. No

0.92; 0.68–1.3

0.61

0.94;

0.73–1.2

0.67

PVTT

Yes vs. No

1.2;

0.91–1.7

0.17

0.98;

0.76–1.3

0.88

PVTT Class

vp 3–4 vs. vp 0–2

1.2;

0.85–1.6

0.89

1.0;

0.8–1.3

0.79

MVI

Yes vs. No

1.3;

1–1.8

0.051

1.0;

0.81–1.3

0.75

ECOG PS

 ≥ 1 vs. 0

1.5;

1.1–2.0

0.018*

1.2;

0.86-1.7

0.28

1.5;

1.1–2

0.005*

1.2;

0.93–1.7

0.14

BMI

 ≥ 25 vs. <25

0.98;

0.72–1.3

0.90

1.0;

0.79–1.3

0.83

BCLC Stage

C vs. A/B

1.3;

0.88–1.8

0.20

0.99; 0.75–1.3

0.96

AFP

 < 400 vs. ≥400

1.0;

0.75–1.4

0.90

0.96;

0.74–1.2

0.75

Child Pugh Class

B vs. A

2.0;

1.5–2.7

<0.001*

1.7; 0.59–1.2

0.002*

1.7;

1.3–2.2

<0.001*

1.4;

1.0–1.9

<0.001*

Etiology

Non-Viral vs. Viral

1.6;

1.1–2.1

0.006*

1.3;

0.96–1.8

0.09

1.5;

1.2–2

0.002*

1.3;

0.97–1.7

0.078

ICI Regimen

Combo vs. Mono

0.57;

0.37–0.86

0.008*

0.71;

0.46-1.1

0.13

0.58;

0.42–0.8

0.001*

0.69;

0.49–0.98

0.036*

Concurrent LRT

Yes vs. No

1.3;

0.95–1.7

0.11

1.1;

0.87–1.4

0.38